NAPSRx Final Exam Test Bank 2025/2026:
Comprehensive Q&A Study Guide
1. A 45-year-old patient with type 2 diabetes and chronic kidney disease (eGFR 35
mL/min/1.73m²) is currently on metformin 1000 mg BID, empagliflozin 10 mg daily, and insulin
glargine 30 units at bedtime. HbA1c is 9.2%. Which of the following medication adjustments is
MOST appropriate to improve glycemic control while minimizing renal risk?
A. Discontinue metformin and add sitagliptin 50 mg daily.
B. Continue metformin, increase empagliflozin to 25 mg daily, and add liraglutide 1.2 mg daily.
C. Discontinue metformin, continue empagliflozin 10 mg, and initiate dulaglutide 0.75 mg weekly.
D. Discontinue empagliflozin, continue metformin, and add glipizide 10 mg daily.
Answer: C
Rationale: Metformin is contraindicated when eGFR <30, but current guidelines recommend
reassessment at eGFR 30-45; however, given eGFR 35 and declining, discontinuation is prudent to
avoid lactic acidosis. Empagliflozin can be continued until eGFR <30, but adding a GLP-1 agonist
(dulaglutide) provides cardiovascular and renal benefits without significant renal clearance. Sitagliptin
requires dose adjustment (50 mg is correct for eGFR 30-50) but does not offer renal protection.
Increasing empagliflozin dose does not improve efficacy and increases risk. Glipizide may cause
hypoglycemia and does not confer renal benefit.
2. In a patient with acute decompensated heart failure with reduced ejection fraction (HFrEF) who
is hypotensive (systolic BP 85 mmHg), which of the following pharmacologic strategies is MOST
appropriate for hemodynamic support while awaiting transplant evaluation?
A. Initiate intravenous milrinone at a low dose and titrate based on blood pressure.
B. Administer intravenous nitroglycerin for preload reduction.
C. Start oral metoprolol succinate 25 mg daily to improve long-term outcomes.
D. Begin intravenous dobutamine and titrate to achieve mean arterial pressure >65 mmHg.
Answer: D
Rationale: In hypotensive acute HFrEF, dobutamine (beta-1 agonist) is preferred for inotropic support to
improve cardiac output and blood pressure. Milrinone (phosphodiesterase-3 inhibitor) is also an
inotrope but can cause hypotension and is typically used in euvolemic patients without hypotension.
Nitroglycerin is a vasodilator and would worsen hypotension. Beta-blockers like metoprolol are
contraindicated in acute decompensation due to negative inotropic effects.
3. A patient with metastatic melanoma is started on nivolumab (PD-1 inhibitor). After three cycles,
they develop new-onset diarrhea (10 episodes/day), abdominal cramping, and blood in stool.
Colonoscopy reveals diffuse colitis with ulceration. Stool studies are negative for infection. Which
of the following is the MOST appropriate next step in management?
A. Immediately discontinue nivolumab and initiate high-dose intravenous methylprednisolone (2 mg/kg/day).
Page 1
,B. Hold nivolumab, start oral budesonide 9 mg daily, and reassess in one week.
C. Continue nivolumab and add loperamide 4 mg initially then 2 mg after each loose stool.
D. Switch to ipilimumab (CTLA-4 inhibitor) and initiate infliximab 5 mg/kg intravenously.
Answer: A
Rationale: This presentation is consistent with grade 3-4 immune-mediated colitis from anti-PD-1
therapy. Per NCCN guidelines, treatment should be permanently discontinued for grade 3-4 toxicity, and
high-dose corticosteroids (IV methylprednisolone 1-2 mg/kg/day) should be initiated. Budesonide is only
for mild (grade 1) colitis. Loperamide is contraindicated in suspected inflammatory colitis due to risk of
toxic megacolon. Switching to ipilimumab may worsen toxicity; infliximab can be considered if no
response to steroids, but not as first-line.
4. A 60-year-old patient with atrial fibrillation (CHA ‚DS ‚-VASc score 4) is on warfarin with a
therapeutic INR range of 2-3. Due to a drug interaction, the INR becomes 5.8 without bleeding.
The patient has no hepatic impairment. Which of the following is the MOST appropriate
management?
A. Hold warfarin for 1-2 days, recheck INR daily, and resume at a lower dose when INR <3.
B. Administer vitamin K 10 mg orally and hold warfarin for 3 days.
C. Give fresh frozen plasma (FFP) 2 units and restart warfarin at the same dose.
D. Administer prothrombin complex concentrate (PCC) 25 units/kg and discontinue warfarin permanently.
Answer: A
Rationale: For an elevated INR >5 but <9 without significant bleeding, guidelines recommend holding
warfarin, monitoring INR, and resuming at a lower dose once INR is therapeutic. Oral vitamin K 2.5-5
mg may be considered if bleeding risk is high, but 10 mg is excessive and may cause warfarin resistance.
FFP and PCC are reserved for major bleeding or need for urgent reversal. Permanent discontinuation is
not indicated.
5. Which of the following statements best describes the mechanism of action of the monoclonal
antibody evolocumab in lowering low-density lipoprotein cholesterol (LDL-C)?
A. It inhibits the enzyme HMG-CoA reductase, reducing cholesterol synthesis in the liver.
B. It binds to and inhibits the proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby increasing the
number of LDL receptors on hepatocytes.
C. It activates the peroxisome proliferator-activated receptor alpha (PPAR±), leading to increased fatty acid
oxidation and reduced triglyceride levels.
D. It increases the expression of the LDL receptor gene by acting as a transcription factor.
Answer: B
Rationale: Evolocumab is a PCSK9 inhibitor. PCSK9 normally binds to LDL receptors and targets them
for degradation. By inhibiting PCSK9, evolocumab increases the number of LDL receptors available to
clear LDL-C from the bloodstream. Option A describes statins. Option C describes fibrates. Option D is
not correct; evolocumab does not affect gene transcription.
6. A patient with treatment-resistant depression has failed adequate trials of two different SSRIs
and one SNRI. They are now started on a monoamine oxidase inhibitor (MAOI). Which of the
following dietary restrictions is MOST critical to prevent a hypertensive crisis?
Page 2
,A. Avoid foods containing high levels of tyramine, such as aged cheeses, cured meats, and soy products.
B. Limit intake of foods rich in tryptophan, such as turkey and milk.
C. Avoid foods with high sodium content to prevent fluid retention.
D. Restrict consumption of caffeine-containing beverages to no more than two cups per day.
Answer: A
Rationale: MAOIs inhibit the breakdown of tyramine, which can cause a sudden release of
norepinephrine leading to hypertensive crisis. Tyramine-rich foods include aged cheeses, cured meats,
fermented foods, and soy sauce. Tryptophan-rich foods are not a concern with MAOIs; they are more
relevant with serotonin syndrome. Sodium and caffeine restrictions are not primary concerns, though
caffeine may have indirect effects.
7. A patient with chronic neuropathic pain due to diabetic peripheral neuropathy has been on
gabapentin 1200 mg daily with partial relief. They report significant sedation and dizziness. Which
of the following is the MOST appropriate next step?
A. Increase gabapentin to 1800 mg daily and add a low-dose tricyclic antidepressant (TCA) such as nortriptyline
10 mg at bedtime.
B. Switch to pregabalin 150 mg daily, titrating slowly, and monitor for sedation.
C. Discontinue gabapentin and initiate duloxetine 60 mg daily, with a plan to add pregabalin if needed.
D. Continue gabapentin at current dose and add topical lidocaine 5% patches to the affected areas.
Answer: C
Rationale: Given inadequate response and intolerable side effects, switching to a different first-line agent
is appropriate. Duloxetine (SNRI) is first-line for diabetic peripheral neuropathy and has a different side
effect profile. Pregabalin has similar side effects to gabapentin (sedation, dizziness) and may not be
better tolerated. Adding a TCA increases anticholinergic burden and sedation. Lidocaine patches are
second-line and may not provide sufficient systemic relief.
8. A patient with severe asthma is started on omalizumab (anti-IgE therapy). Which of the
following parameters is MOST important to monitor during the first month of therapy?
A. Peak expiratory flow rate (PEFR) variability and daily symptom diary.
B. Serum IgE levels every two weeks to adjust dose.
C. Complete blood count with differential to monitor for eosinophilia.
D. Blood pressure and heart rate before and after each injection.
Answer: A
Rationale: Omalizumab is a monoclonal antibody that reduces free IgE and downregulates FcµRI
receptors. Monitoring response includes assessing asthma control via PEFR, symptom scores, and
exacerbation frequency. Serum IgE levels are not used for dose adjustment after initial dosing;
omalizumab can increase total IgE levels. Eosinophilia is not a routine monitoring parameter. Blood
pressure and heart rate are not specifically affected, though anaphylaxis risk requires observation after
injection.
9. A patient with acute bacterial sinusitis has been on amoxicillin-clavulanate 875/125 mg BID for 5
days without improvement. They have no drug allergies. Which of the following is the MOST
appropriate alternative therapy?
Page 3
, A. Switch to cefdinir 300 mg BID for 10 days.
B. Add a nasal corticosteroid and continue current antibiotic for another 5 days.
C. Change to levofloxacin 750 mg daily for 7 days.
D. Obtain a sinus culture via endoscopy and tailor therapy based on results.
Answer: C
Rationale: In cases of clinical failure after 5 days of first-line therapy, a respiratory fluoroquinolone
(levofloxacin or moxifloxacin) is recommended due to its coverage of resistant pathogens including S.
pneumoniae and H. influenzae. Cefdinir is a third-generation cephalosporin but may have reduced
activity against penicillin-resistant strains. Adding a nasal corticosteroid is adjunctive but not a
substitute for effective antibiotic therapy. Sinus culture is invasive and not routinely recommended for
uncomplicated cases; empiric therapy change is appropriate.
10. A patient with osteoporosis (T-score -3.2 at lumbar spine) is started on denosumab 60 mg
subcutaneously every 6 months. After 3 doses, they miss a dose by 4 months. Which of the
following is the MOST appropriate management?
A. Administer the missed dose immediately and continue every 6 months from that date.
B. Administer a loading dose of 120 mg and then resume 60 mg every 6 months.
C. Discontinue denosumab and start alendronate 70 mg weekly.
D. Check bone mineral density (BMD) and if stable, do not administer the missed dose.
Answer: A
Rationale: Denosumab should not be delayed beyond 7 months due to risk of rapid bone loss and rebound
fractures. If a dose is missed, it should be given as soon as possible, and the dosing schedule should be
reset. A loading dose is not necessary. Discontinuation without a transition to another antiresorptive
(e.g., bisphosphonate) can lead to rapid bone loss and increased fracture risk. BMD monitoring is not
appropriate to decide on dosing; the missed dose should be given regardless.
11. A patient with a history of recurrent major depressive disorder has been on fluoxetine 40 mg
daily for 6 months with partial response. The clinician decides to augment with a
second-generation antipsychotic. Which of the following mechanisms best explains the rationale for
this augmentation strategy?
A. Antagonism of 5-HT2A receptors enhances dopaminergic transmission in prefrontal cortex
B. Partial agonism at D2 receptors increases dopamine release in the mesolimbic pathway
C. Inhibition of serotonin reuptake potentiates the effect of the antipsychotic on NMDA receptors
D. Blockade of histamine H1 receptors improves sleep and reduces depressive rumination
Answer: A
Rationale: Augmentation with second-generation antipsychotics like aripiprazole or quetiapine targets
5-HT2A antagonism, which disinhibits dopamine and norepinephrine release in prefrontal cortex,
enhancing antidepressant efficacy. Option B describes aripiprazole's partial D2 agonism but is not the
primary mechanism for augmentation. Options C and D are not central to the rationale; histamine
blockade is sedating but not directly antidepressant.
Page 4
Comprehensive Q&A Study Guide
1. A 45-year-old patient with type 2 diabetes and chronic kidney disease (eGFR 35
mL/min/1.73m²) is currently on metformin 1000 mg BID, empagliflozin 10 mg daily, and insulin
glargine 30 units at bedtime. HbA1c is 9.2%. Which of the following medication adjustments is
MOST appropriate to improve glycemic control while minimizing renal risk?
A. Discontinue metformin and add sitagliptin 50 mg daily.
B. Continue metformin, increase empagliflozin to 25 mg daily, and add liraglutide 1.2 mg daily.
C. Discontinue metformin, continue empagliflozin 10 mg, and initiate dulaglutide 0.75 mg weekly.
D. Discontinue empagliflozin, continue metformin, and add glipizide 10 mg daily.
Answer: C
Rationale: Metformin is contraindicated when eGFR <30, but current guidelines recommend
reassessment at eGFR 30-45; however, given eGFR 35 and declining, discontinuation is prudent to
avoid lactic acidosis. Empagliflozin can be continued until eGFR <30, but adding a GLP-1 agonist
(dulaglutide) provides cardiovascular and renal benefits without significant renal clearance. Sitagliptin
requires dose adjustment (50 mg is correct for eGFR 30-50) but does not offer renal protection.
Increasing empagliflozin dose does not improve efficacy and increases risk. Glipizide may cause
hypoglycemia and does not confer renal benefit.
2. In a patient with acute decompensated heart failure with reduced ejection fraction (HFrEF) who
is hypotensive (systolic BP 85 mmHg), which of the following pharmacologic strategies is MOST
appropriate for hemodynamic support while awaiting transplant evaluation?
A. Initiate intravenous milrinone at a low dose and titrate based on blood pressure.
B. Administer intravenous nitroglycerin for preload reduction.
C. Start oral metoprolol succinate 25 mg daily to improve long-term outcomes.
D. Begin intravenous dobutamine and titrate to achieve mean arterial pressure >65 mmHg.
Answer: D
Rationale: In hypotensive acute HFrEF, dobutamine (beta-1 agonist) is preferred for inotropic support to
improve cardiac output and blood pressure. Milrinone (phosphodiesterase-3 inhibitor) is also an
inotrope but can cause hypotension and is typically used in euvolemic patients without hypotension.
Nitroglycerin is a vasodilator and would worsen hypotension. Beta-blockers like metoprolol are
contraindicated in acute decompensation due to negative inotropic effects.
3. A patient with metastatic melanoma is started on nivolumab (PD-1 inhibitor). After three cycles,
they develop new-onset diarrhea (10 episodes/day), abdominal cramping, and blood in stool.
Colonoscopy reveals diffuse colitis with ulceration. Stool studies are negative for infection. Which
of the following is the MOST appropriate next step in management?
A. Immediately discontinue nivolumab and initiate high-dose intravenous methylprednisolone (2 mg/kg/day).
Page 1
,B. Hold nivolumab, start oral budesonide 9 mg daily, and reassess in one week.
C. Continue nivolumab and add loperamide 4 mg initially then 2 mg after each loose stool.
D. Switch to ipilimumab (CTLA-4 inhibitor) and initiate infliximab 5 mg/kg intravenously.
Answer: A
Rationale: This presentation is consistent with grade 3-4 immune-mediated colitis from anti-PD-1
therapy. Per NCCN guidelines, treatment should be permanently discontinued for grade 3-4 toxicity, and
high-dose corticosteroids (IV methylprednisolone 1-2 mg/kg/day) should be initiated. Budesonide is only
for mild (grade 1) colitis. Loperamide is contraindicated in suspected inflammatory colitis due to risk of
toxic megacolon. Switching to ipilimumab may worsen toxicity; infliximab can be considered if no
response to steroids, but not as first-line.
4. A 60-year-old patient with atrial fibrillation (CHA ‚DS ‚-VASc score 4) is on warfarin with a
therapeutic INR range of 2-3. Due to a drug interaction, the INR becomes 5.8 without bleeding.
The patient has no hepatic impairment. Which of the following is the MOST appropriate
management?
A. Hold warfarin for 1-2 days, recheck INR daily, and resume at a lower dose when INR <3.
B. Administer vitamin K 10 mg orally and hold warfarin for 3 days.
C. Give fresh frozen plasma (FFP) 2 units and restart warfarin at the same dose.
D. Administer prothrombin complex concentrate (PCC) 25 units/kg and discontinue warfarin permanently.
Answer: A
Rationale: For an elevated INR >5 but <9 without significant bleeding, guidelines recommend holding
warfarin, monitoring INR, and resuming at a lower dose once INR is therapeutic. Oral vitamin K 2.5-5
mg may be considered if bleeding risk is high, but 10 mg is excessive and may cause warfarin resistance.
FFP and PCC are reserved for major bleeding or need for urgent reversal. Permanent discontinuation is
not indicated.
5. Which of the following statements best describes the mechanism of action of the monoclonal
antibody evolocumab in lowering low-density lipoprotein cholesterol (LDL-C)?
A. It inhibits the enzyme HMG-CoA reductase, reducing cholesterol synthesis in the liver.
B. It binds to and inhibits the proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby increasing the
number of LDL receptors on hepatocytes.
C. It activates the peroxisome proliferator-activated receptor alpha (PPAR±), leading to increased fatty acid
oxidation and reduced triglyceride levels.
D. It increases the expression of the LDL receptor gene by acting as a transcription factor.
Answer: B
Rationale: Evolocumab is a PCSK9 inhibitor. PCSK9 normally binds to LDL receptors and targets them
for degradation. By inhibiting PCSK9, evolocumab increases the number of LDL receptors available to
clear LDL-C from the bloodstream. Option A describes statins. Option C describes fibrates. Option D is
not correct; evolocumab does not affect gene transcription.
6. A patient with treatment-resistant depression has failed adequate trials of two different SSRIs
and one SNRI. They are now started on a monoamine oxidase inhibitor (MAOI). Which of the
following dietary restrictions is MOST critical to prevent a hypertensive crisis?
Page 2
,A. Avoid foods containing high levels of tyramine, such as aged cheeses, cured meats, and soy products.
B. Limit intake of foods rich in tryptophan, such as turkey and milk.
C. Avoid foods with high sodium content to prevent fluid retention.
D. Restrict consumption of caffeine-containing beverages to no more than two cups per day.
Answer: A
Rationale: MAOIs inhibit the breakdown of tyramine, which can cause a sudden release of
norepinephrine leading to hypertensive crisis. Tyramine-rich foods include aged cheeses, cured meats,
fermented foods, and soy sauce. Tryptophan-rich foods are not a concern with MAOIs; they are more
relevant with serotonin syndrome. Sodium and caffeine restrictions are not primary concerns, though
caffeine may have indirect effects.
7. A patient with chronic neuropathic pain due to diabetic peripheral neuropathy has been on
gabapentin 1200 mg daily with partial relief. They report significant sedation and dizziness. Which
of the following is the MOST appropriate next step?
A. Increase gabapentin to 1800 mg daily and add a low-dose tricyclic antidepressant (TCA) such as nortriptyline
10 mg at bedtime.
B. Switch to pregabalin 150 mg daily, titrating slowly, and monitor for sedation.
C. Discontinue gabapentin and initiate duloxetine 60 mg daily, with a plan to add pregabalin if needed.
D. Continue gabapentin at current dose and add topical lidocaine 5% patches to the affected areas.
Answer: C
Rationale: Given inadequate response and intolerable side effects, switching to a different first-line agent
is appropriate. Duloxetine (SNRI) is first-line for diabetic peripheral neuropathy and has a different side
effect profile. Pregabalin has similar side effects to gabapentin (sedation, dizziness) and may not be
better tolerated. Adding a TCA increases anticholinergic burden and sedation. Lidocaine patches are
second-line and may not provide sufficient systemic relief.
8. A patient with severe asthma is started on omalizumab (anti-IgE therapy). Which of the
following parameters is MOST important to monitor during the first month of therapy?
A. Peak expiratory flow rate (PEFR) variability and daily symptom diary.
B. Serum IgE levels every two weeks to adjust dose.
C. Complete blood count with differential to monitor for eosinophilia.
D. Blood pressure and heart rate before and after each injection.
Answer: A
Rationale: Omalizumab is a monoclonal antibody that reduces free IgE and downregulates FcµRI
receptors. Monitoring response includes assessing asthma control via PEFR, symptom scores, and
exacerbation frequency. Serum IgE levels are not used for dose adjustment after initial dosing;
omalizumab can increase total IgE levels. Eosinophilia is not a routine monitoring parameter. Blood
pressure and heart rate are not specifically affected, though anaphylaxis risk requires observation after
injection.
9. A patient with acute bacterial sinusitis has been on amoxicillin-clavulanate 875/125 mg BID for 5
days without improvement. They have no drug allergies. Which of the following is the MOST
appropriate alternative therapy?
Page 3
, A. Switch to cefdinir 300 mg BID for 10 days.
B. Add a nasal corticosteroid and continue current antibiotic for another 5 days.
C. Change to levofloxacin 750 mg daily for 7 days.
D. Obtain a sinus culture via endoscopy and tailor therapy based on results.
Answer: C
Rationale: In cases of clinical failure after 5 days of first-line therapy, a respiratory fluoroquinolone
(levofloxacin or moxifloxacin) is recommended due to its coverage of resistant pathogens including S.
pneumoniae and H. influenzae. Cefdinir is a third-generation cephalosporin but may have reduced
activity against penicillin-resistant strains. Adding a nasal corticosteroid is adjunctive but not a
substitute for effective antibiotic therapy. Sinus culture is invasive and not routinely recommended for
uncomplicated cases; empiric therapy change is appropriate.
10. A patient with osteoporosis (T-score -3.2 at lumbar spine) is started on denosumab 60 mg
subcutaneously every 6 months. After 3 doses, they miss a dose by 4 months. Which of the
following is the MOST appropriate management?
A. Administer the missed dose immediately and continue every 6 months from that date.
B. Administer a loading dose of 120 mg and then resume 60 mg every 6 months.
C. Discontinue denosumab and start alendronate 70 mg weekly.
D. Check bone mineral density (BMD) and if stable, do not administer the missed dose.
Answer: A
Rationale: Denosumab should not be delayed beyond 7 months due to risk of rapid bone loss and rebound
fractures. If a dose is missed, it should be given as soon as possible, and the dosing schedule should be
reset. A loading dose is not necessary. Discontinuation without a transition to another antiresorptive
(e.g., bisphosphonate) can lead to rapid bone loss and increased fracture risk. BMD monitoring is not
appropriate to decide on dosing; the missed dose should be given regardless.
11. A patient with a history of recurrent major depressive disorder has been on fluoxetine 40 mg
daily for 6 months with partial response. The clinician decides to augment with a
second-generation antipsychotic. Which of the following mechanisms best explains the rationale for
this augmentation strategy?
A. Antagonism of 5-HT2A receptors enhances dopaminergic transmission in prefrontal cortex
B. Partial agonism at D2 receptors increases dopamine release in the mesolimbic pathway
C. Inhibition of serotonin reuptake potentiates the effect of the antipsychotic on NMDA receptors
D. Blockade of histamine H1 receptors improves sleep and reduces depressive rumination
Answer: A
Rationale: Augmentation with second-generation antipsychotics like aripiprazole or quetiapine targets
5-HT2A antagonism, which disinhibits dopamine and norepinephrine release in prefrontal cortex,
enhancing antidepressant efficacy. Option B describes aripiprazole's partial D2 agonism but is not the
primary mechanism for augmentation. Options C and D are not central to the rationale; histamine
blockade is sedating but not directly antidepressant.
Page 4
